Market brief — October 6, 2026

Yesterday, Monday’s session showed a sharp cross-asset divergence: the CAC 40 closed at 7,834.10, down 0.80%, while the S&P 500 rose 0.66% to 7,773.95, the Nasdaq gained 1.05% to 27,477.31, the DAX added 0.09% to 25,254.21, and the Euro Stoxx 50 advanced 0.06% to 6,242.14. The move was not a clean risk-on repricing: U.S. technology absorbed higher discount rates, while European equities reflected renewed fiscal and political stress. The U.S. 10-year yield reached 5.31%, a multi-year extreme, even as the dollar strengthened and markets reduced the probability of an October Fed hike to roughly 24% after weaker September labor data.^[1][2][3]

The dominant regime is therefore a bond-market credibility shock combined with selective equity duration buying. Treasury weakness reflects heavy issuance, elevated energy costs and concern over public finances; German 10-year yields rose to 3.49%, while French fiscal stress pushed the euro toward a 17-month low.^[2][5] The important divergence is that Nasdaq leadership persisted despite higher yields. That points less to broad discretionary risk-taking than to concentrated megacap, systematic and short-covering flows. It can extend while yields stabilize, but becomes vulnerable if the 10-year yield breaks decisively above 5.3% or if the dollar’s advance tightens global financial conditions. Oil offered some relief, with Brent around $100.32 after higher Middle Eastern exports and a G7 supply commitment, although geopolitical disruption risk remains.^[3]

The Cash Scanner reinforces a momentum-led, highly idiosyncratic tape rather than a broad macro rotation. Novavax (NVAX) scored 41 with a 20.1% gap, a bullish MACD and rising volume, while Recursion Pharmaceuticals (RXRX) scored 36 after a 16.0% gap and a 20-day breakout; biotechnology is attracting event-driven capital. Semiconductor leadership remains visible through Analog Devices (ADI), score 39 and +0.5%, with ADX 27, and NVIDIA (NVDA), score 37 and +2.1%, showing a 20-day breakout and rising volume. Petrobras (PBR), score 39 and +11.5%, adds an energy and emerging-market component. With two biotechnology, two semiconductor and two energy/materials/industrials names, the scan confirms speculative momentum and selective commodity exposure, not generalized European risk appetite.

Over the next one to five sessions, consensus is that weaker labor data has removed the immediate October tightening threat. That is partly priced in; the underappreciated risk is that long-end yields continue rising independently of near-term Fed expectations because of term premium, fiscal supply and inflation-sensitive energy prices. A contrarian bullish scenario is that Treasury yields consolidate below 5.3%, allowing the Nasdaq and high-beta scanner names to extend. The bearish alternative is an equity rally that fails because rates, rather than the policy path, are the binding constraint.

The highest-impact catalysts are further U.S. rate and Fed communication, which could validate or reverse the sharp repricing of October hike odds; developments in French fiscal politics, which could widen European sovereign spreads and pressure the euro; and oil-market headlines linked to Middle Eastern supply, which could revive inflation expectations. U.S. data confirming labor cooling would support duration, whereas resilient services or inflation data would challenge the current equity bid.

Key risks are a disorderly Treasury auction or further long-end selling, renewed French contagion into peripheral European spreads, and an oil supply shock that lifts inflation expectations while weakening consumption. A fourth risk is momentum exhaustion in biotechnology and semiconductor leaders after large scanner gaps.

Actionably, treat 5.30–5.35% in the U.S. 10-year yield as the regime trigger: stabilization below it favors NVIDIA, Analog Devices and the Nasdaq; a sustained break above it invalidates the duration trade. Monitor the dollar against the euro: renewed euro weakness alongside higher yields would argue for reducing crowded growth exposure and favoring Petrobras, while dollar stabilization would support continuation. Finally, require volume confirmation before chasing Novavax or Recursion Pharmaceuticals; fading volume and a reversal below their breakout zones would signal that the scanner is registering short covering rather than durable accumulation.

Bonne journée aux p&l makers.